Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI’s medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company’s radiopharmaceutical pipeline.

“My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effective approach to TRT. I am thrilled to be supporting the team in leading EVA101 and EVA102 through the critical final stages of development,” said Danielle Meyrick, CMO of MTTI.

Dr. Chris Pak, President & CEO commented “MTTI is delighted to welcome Dr. Danielle Meyrick, an experienced clinician and executive. Her perspective and track record in TRT development are key complements to our team as we expedite advancement of our targeted radiotherapeutic pipeline.”

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics (TRT). MTTI is committed to building value by translating innovative TRT to improve human healthcare. For more information: www.mtarget.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250723997060/en/